Abstract
It is well known that patients who have undergone organ transplantation (Tx) have an increased risk of developing de novo malignancies (100 times what is observed in the general population). The more frequent malignancies after Tx are carcinoma of the skin and lips, lymphoproliferative disorders and Kaposi’s sarcoma. All of them are strongly associated with viral infections (Epstein Barr virus, Human Papilomas virus, Human herpes virus 8) [1, 2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sheil AGR. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992; 24: 1275–1279.
Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101–1103.
Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262–4279.
Penn I. Lymphomas complicating organ transplantation. Transplant Proc 1983; 15: 2790–2797.
Nalesnick MA, Makowka L, Starzl TE. The diagnosis and treatment of post-transplant lymphoproliferative disorders. Curr Prob Surg 1988; 25: 371–382.
Penn I. Tumor incidence in human allograft recipients. Transplant Proc 1979; 11: 1047–1051.
Morisson VA, Dunn MD, Manivel JC et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14–24.
Opelz G, Henderson R. For the collaborative transplant study. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342; 1514–1516.
Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (5EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983; 198: 356–368.
Starzl TE, Porter KA, Iwatsuki S. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 1: 583–587.
Stephanian E, Gruber SA, Dunn DL et al. Posttransplant lymphoproliferative disorders. Transplant Rev 1991; 5: 120–129.
Nalesnik Ma, Jaffe R, Starzl et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173–192.
Cockfield SM, Preiksaitis J, Harvey E et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106–1107.
Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr Virus lymphoproliferation after bone marrow transplantation. Blood 1988; 712: 520–529.
Swinnen LJ, Costanzo-Nordin MK, Fischer SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723–1728.
Renard T, Andrews W, Foster ME. Relationship between OKT3 administration, EBV seroconversion and lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473–1476.
Lopatin WB, Hickey DP, Nalesnik MA et al. Post-transplant lymphoproliferative disease and triple therapy. Clin Transplant 1990; 4: 47–52.
Wilkinson AH, Smith JL, Hunsicker LG et al. Increased frequency of post-transplant lymphomas in patients treated with cyclosporine azathioprine, and prednisone Transplantation 1989; 47: 293–296.
Randhawa PS, Jaffe R, Demetris AJ et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327: 1710–1714.
Rea D, Fourcade C, Leblond V et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994; 58: 317–324.
Young L, Alfieri C, Hennessy K et al. Expression of Epstein Barr Virus transformation- associated genes in tissues of patients with EBV lymphoproliferative disease N Engl J Med 1989; 321: 1080–1085.
Lee ES, Locker J, Nalesnik M et al. The association of Epstein-Barr virus with smooth- muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332: 19–25.
Rowe M, Young S, Crocker J et al. Epstein Barr Virus associated lymphoproliferative disease in the SCID mouse model: implication of EBV-positive lymphomas in man J Exp Med 1991; 173: 147–156.
Bird AG, McLachlan SM, Britton S. Cyclosporine A promotes spontaneous outgrowth in vitro of Epstein-Barr virus induced B-cell lines. Nature 1981; 289: 300–301.
Cox KL, Lawrence-Miyasaki, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995; 59: 524–529.
Ho M, Miller G, Atchison RW et al. Epstein Barr Virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions. The role of primary infection. J Infect Dis 1985; 152: 876–886.
Ferry JA, Jacobson JO, Conti D et al. Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989; 2: 583–592.
Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients Transplantation 1995; 59: 240–244.
Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of Cyclosporine A-Prednisone immunosuppression Am J Pathol 1988; 133: 173–192.
Hanto DW, Birkenbach M, Frizzera G et al. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458–464.
Patton DF, Wilkowski CW, Hanson CA et al. Epstein-Barr virus-determined clonality in postransplant lymphoproliferative disease. Transplantation 1990; 49: 1080–1084.
Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorders Transplantation 1992; 54: 250–253.
Griffith RC, Saha BK, Janney CM et al. Immunoblastic lymphoma of T-cell type in a chronically immunosuppressed renal transplant recipient. AJCP 1990; 93: 280–285.
Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin disease after renal transplantation. Transplantation 1995; (in press).
Hjelle B, Evans-Holms M, Yen TSB et al. A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplant Proc 1989; 47: 945–948.
Meduri G, Fromentin L, Vieillefond A et al. Donor-related non-Hodgkin’s lymphoma in a renal allograft recipient. Transplant Proc 1991; 23: 2649.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Dantal, J. et al. (1996). Clinical characteristics of lymphoproliferations after renal transplantation. Nantes experience. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Cancer in Transplantation: Prevention and Treatment. Transplantation and Clinical Immunology, vol 27. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0175-9_29
Download citation
DOI: https://doi.org/10.1007/978-94-009-0175-9_29
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6563-4
Online ISBN: 978-94-009-0175-9
eBook Packages: Springer Book Archive